Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double‐blind, placebo‐controlled trial
Authors' conclusion
Treatment with liraglutide improves residual beta-cell function and reduces the dose of insulin during the first year after diagnosis. Beta-cell function was similar at 6 weeks postliraglutide treatment.
Study context
- Population
- Adults with newly diagnosed T1D and stimulated C-peptide >0.2 nmol/Lrandomized 1:1
- Participants
- 68 adults
- Comparison
- Liraglutide 1.8 mg once daily vs placebo for 52 weeks
- Primary endpoint
- Between-group difference in C-peptide AUC following a liquid mixed-meal test
- Follow-up
- 52 weeks
Methodological detailsmulticentre, double-blind, placebo-controlled, parallel-group, 6 weeks of follow-up with only insulin treatment after 52 weeks
- Multicentre
- Double-blind
- Placebo-controlled
- Parallel-group
- 6 weeks of follow-up with only insulin treatment after 52 weeks
Primary result
As reported in the abstract
4-hour AUC C-peptide response
- C-peptide AUC maintained with liraglutide, decreased with placebo
- Liraglutide vs Placebo: P = 0.002
Further findings
Weeks
| Outcome | Liraglutide | Placebo |
|---|---|---|
| Time without need for insulin treatment | ||
| Average duration | 22 (from 3 to 52 weeks) | 6 (from 4 to 8 weeks) |
- Total daily insulin dose · week 52
- P < 0.001
C-peptide AUC 6 weeks after end of treatment
- C-peptide AUCs similar for liraglutide and placebo
Total daily insulin dose · week 52
- Liraglutide: decreased from 0.30 to 0.23 units/kg/day
- Placebo: increased from 0.29 to 0.43 units/kg/day
Safety
- Fewer episodes of hypoglycaemia with liraglutide vs placebo
- Adverse events with liraglutide predominantly gastrointestinal and transient
Original publication
Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double‐blind, placebo‐controlled trial. Diabetes Obes Metab. Published 27 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →